EA201490364A1 - Костимулирующие рецепторы-переключатели - Google Patents

Костимулирующие рецепторы-переключатели

Info

Publication number
EA201490364A1
EA201490364A1 EA201490364A EA201490364A EA201490364A1 EA 201490364 A1 EA201490364 A1 EA 201490364A1 EA 201490364 A EA201490364 A EA 201490364A EA 201490364 A EA201490364 A EA 201490364A EA 201490364 A1 EA201490364 A1 EA 201490364A1
Authority
EA
Eurasian Patent Office
Prior art keywords
receptors
costimulating
switching
negative
positive
Prior art date
Application number
EA201490364A
Other languages
English (en)
Inventor
Карл Х. Джун
Янбин Чжао
Original Assignee
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47629855&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201490364(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания filed Critical Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания
Publication of EA201490364A1 publication Critical patent/EA201490364A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/17—Hinge-spacer domain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В общих чертах изобретение относится к слитому белку, который при его представлении на клетке может преобразовывать передаваемый клетке отрицательный сигнал в положительный сигнал. Слитый белок представляет собой химерный белок, т.е. белок, содержащий по меньшей мере два домена, где первым доменом является полипептид, который связан с отрицательным сигналом, а вторым доменом является полипептид, который связан с положительным сигналом. Так, например, изобретение охватывает рецепторы-переключатели, обладающие способностью преобразовывать отрицательные сигналы в положительные сигналы, и, тем самым, усиливать иммунный ответ.
EA201490364A 2011-07-29 2012-07-27 Костимулирующие рецепторы-переключатели EA201490364A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161513259P 2011-07-29 2011-07-29
PCT/US2012/048543 WO2013019615A2 (en) 2011-07-29 2012-07-27 Switch costimulatory receptors

Publications (1)

Publication Number Publication Date
EA201490364A1 true EA201490364A1 (ru) 2014-08-29

Family

ID=47629855

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490364A EA201490364A1 (ru) 2011-07-29 2012-07-27 Костимулирующие рецепторы-переключатели

Country Status (21)

Country Link
US (2) US10981969B2 (ru)
EP (3) EP3915588A1 (ru)
JP (4) JP6334398B2 (ru)
KR (1) KR20140045533A (ru)
CN (3) CN107266584B (ru)
AU (1) AU2012290342A1 (ru)
BR (1) BR112014002006A2 (ru)
CA (1) CA2842368A1 (ru)
CL (1) CL2014000195A1 (ru)
CO (1) CO6862107A2 (ru)
EA (1) EA201490364A1 (ru)
EC (1) ECSP14013186A (ru)
ES (2) ES2888651T3 (ru)
GT (1) GT201400015A (ru)
IL (1) IL230496A0 (ru)
MA (1) MA35360B1 (ru)
MX (1) MX2014001222A (ru)
PE (1) PE20141520A1 (ru)
TN (1) TN2014000020A1 (ru)
WO (1) WO2013019615A2 (ru)
ZA (1) ZA201400477B (ru)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107266584B (zh) * 2011-07-29 2022-05-13 宾夕法尼亚大学董事会 转换共刺激受体
JP6074435B2 (ja) * 2011-10-26 2017-02-01 ナショナル キャンサー センター 変異ｃｔｌａ４遺伝子移入ｔ細胞及びこれを含む抗がん免疫治療用組成物
CA2868439C (en) 2012-03-28 2023-09-26 Umc Utrecht Holding B.V. Combinatorial gamma 9 delta 2 t cell receptor chain exchange
EP3276000A3 (en) 2012-05-25 2018-02-21 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
NZ746914A (en) 2012-10-02 2020-03-27 Memorial Sloan Kettering Cancer Center Compositions and methods for immunotherapy
ES2814962T3 (es) 2013-02-20 2021-03-29 Novartis Ag Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
WO2014130657A1 (en) 2013-02-20 2014-08-28 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
LT2961831T (lt) 2013-02-26 2020-11-10 Memorial Sloan Kettering Cancer Center Kompozicijos ir būdai, skirti imunoterapijai
KR102466666B1 (ko) 2013-03-15 2022-11-15 메모리얼 슬로안 케터링 캔서 센터 면역치료용 조성물 및 방법
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
JP6578271B2 (ja) * 2013-04-17 2019-09-18 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 免疫抑制ＴＧＦ−βシグナルコンバーター
EA036200B1 (ru) * 2013-05-13 2020-10-14 Селлектис Cd19-специфический химерный антигенный рецептор и его применения
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
KR102339240B1 (ko) * 2013-10-15 2021-12-15 더 스크립스 리서치 인스티튜트 펩타이드 키메라 항원 수용체 t 세포 스위치 및 이의 용도
CA2931684C (en) * 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) * 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
CA2940671A1 (en) 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
SG11201700476VA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
BR112017000939A2 (pt) 2014-07-21 2017-11-14 Novartis Ag tratamento de câncer usando um receptor antigênico quimérico de cll-1
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP4205749A1 (en) 2014-07-31 2023-07-05 Novartis AG Subset-optimized chimeric antigen receptor-containing cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
DK3183268T3 (da) 2014-08-19 2020-05-11 Univ Pennsylvania Behandling af cancer ved anvendelse af en cd123-kimær antigenreceptor
CN114621969A (zh) 2014-09-17 2022-06-14 诺华股份有限公司 用于过继免疫疗法的具有嵌合受体的靶向细胞毒性细胞
SG11201702895SA (en) 2014-10-08 2017-05-30 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
WO2016070061A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US10973895B2 (en) 2014-11-20 2021-04-13 Umc Utrecht Holding B.V. Use of antibodies for enrichment of engineered T cells with exogenous immune receptors and antibodies for use in depletion of engineered T cells
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
EP4223873A3 (en) * 2015-01-31 2023-09-06 The Trustees of the University of Pennsylvania Compositions and methods for t cell delivery of therapeutic molecules
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CA2976684C (en) * 2015-03-02 2024-03-05 Innovative Cellular Therapeutics CO., LTD. Reducing immune tolerance induced by pd-l1
MY196588A (en) * 2015-03-05 2023-04-19 Hutchinson Fred Cancer Res Immunomodulatory Fusion Proteins and uses Thereof
US10800828B2 (en) 2015-03-26 2020-10-13 The Scripps Research Institute Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
EP3404411A3 (en) * 2015-03-31 2019-02-13 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
US11091546B2 (en) 2015-04-15 2021-08-17 The Scripps Research Institute Optimized PNE-based chimeric receptor T cell switches and uses thereof
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
PL3310805T3 (pl) * 2015-06-19 2021-08-23 Sebastian KOBOLD Białka fuzyjne pd-1-cd28 i ich zastosowanie w medycynie
WO2016210129A1 (en) * 2015-06-23 2016-12-29 Memorial Sloan-Kettering Cancer Center Novel pd-1 immune modulating agents
KR20180038447A (ko) * 2015-06-29 2018-04-16 더 존스 홉킨스 유니버시티 면역 체크포인트 키메라 수용체 치료법
US11059880B2 (en) 2015-06-30 2021-07-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Redirected cells with MHC chimeric receptors and methods of use in immunotherapy
EP3325504A1 (en) 2015-07-21 2018-05-30 Novartis AG Methods for improving the efficacy and expansion of immune cells
GB201513540D0 (en) 2015-07-31 2015-09-16 King S College London Therapeutic agents
WO2017027392A1 (en) 2015-08-07 2017-02-16 Novartis Ag Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (zh) 2015-09-03 2022-07-22 诺华股份有限公司 预测细胞因子释放综合征的生物标志物
CA2997551A1 (en) * 2015-09-04 2017-03-09 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of use
MA44909A (fr) 2015-09-15 2018-07-25 Acerta Pharma Bv Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
UA126549C2 (uk) 2015-10-01 2022-11-02 Хіт Байолоджикс, Інк. Композиція і спосіб для з'єднання позаклітинних доменів типу і та типу іі як гетерологічного химерного білка
CN105331585A (zh) 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN108699557A (zh) 2015-12-04 2018-10-23 诺华股份有限公司 用于免疫肿瘤学的组合物和方法
AU2016366226B2 (en) * 2015-12-09 2023-06-01 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same
EP3393504A1 (en) 2015-12-22 2018-10-31 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
CN109195985B (zh) * 2016-03-23 2022-07-26 德国亥姆霍兹慕尼黑中心健康与环境研究中心（有限公司） Pd-1和4-1bb的融合蛋白
CA3027124A1 (en) 2016-06-10 2017-12-14 Umc Utrecht Holding B.V. Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response
CN107586342A (zh) * 2016-07-08 2018-01-16 生命序有限公司 重组免疫检查点受体及其应用
WO2018012895A1 (ko) * 2016-07-14 2018-01-18 주식회사 큐로셀 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물
JP7219376B2 (ja) 2016-07-15 2023-02-08 ノバルティス アーゲー キメラ抗原受容体をキナーゼ阻害薬と併用して使用したサイトカイン放出症候群の治療及び予防
AU2017317022B2 (en) * 2016-08-26 2021-12-09 Baylor College Of Medicine Constitutively active cytokine receptors for cell therapy
CN109863242A (zh) 2016-08-30 2019-06-07 纪念斯隆-凯特林癌症中心 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法
CN110139873A (zh) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
US10525083B2 (en) 2016-10-07 2020-01-07 Novartis Ag Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
JP7149935B2 (ja) 2016-10-19 2022-10-07 ザ スクリプス リサーチ インスティテュート ヒト化された標的化部分および／または最適化されたキメラ抗原受容体相互作用ドメインを有する、キメラ抗原受容体エフェクター細胞スイッチ、ならびにその使用
CN107988164B (zh) 2016-10-26 2020-07-07 阿思科力(苏州)生物科技有限公司 一种pd-1 car nk-92细胞及其制备方法与应用
US11851491B2 (en) 2016-11-22 2023-12-26 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
KR20190096969A (ko) * 2016-12-22 2019-08-20 윈드밀 테라퓨틱스, 인크. 면역계를 조절하기 위한 조성물 및 방법
US10613083B2 (en) 2016-12-22 2020-04-07 Fundamental Solutions Corporation Universal biosensor system for analyte detection
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
SG11201906464UA (en) 2017-02-27 2019-08-27 Shattuck Labs Inc Csf1r-based chimeric proteins
US11192933B2 (en) 2017-02-27 2021-12-07 Shattuck Labs, Inc. VSIG8-based chimeric proteins
CA3054127A1 (en) 2017-02-27 2018-08-30 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
JP7178355B2 (ja) 2017-02-28 2022-11-25 エンドサイト・インコーポレイテッド Ｃａｒ ｔ細胞療法のための組成物および方法
WO2018170475A1 (en) 2017-03-17 2018-09-20 Fred Hutchinson Cancer Research Center Immunomodulatory fusion proteins and uses thereof
WO2018175636A2 (en) 2017-03-22 2018-09-27 Novartis Ag Compositions and methods for immunooncology
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN108977453A (zh) * 2017-06-02 2018-12-11 阿思科力(苏州)生物科技有限公司 一种以robo1为靶点的嵌合抗原受体细胞及其制备和应用
CN111148533A (zh) 2017-09-19 2020-05-12 麻省理工学院 用于嵌合抗原受体t细胞疗法的组合物及其用途
JP2020536531A (ja) * 2017-09-26 2020-12-17 ロングウッド ユニバーシティーＬｏｎｇｗｏｏｄ Ｕｎｉｖｅｒｓｉｔｙ 免疫療法としてのｐｄ１特異的キメラ抗原受容体
KR20200104284A (ko) 2017-10-03 2020-09-03 주노 쎄러퓨티크스 인코퍼레이티드 Hpv-특이적 결합 분자
JP2021501570A (ja) 2017-10-18 2021-01-21 ノバルティス アーゲー 選択的タンパク質分解のための組成物及び方法
WO2019091478A1 (en) 2017-11-10 2019-05-16 Chineo Medical Technology Co., Ltd. Modified immune cells and uses thereof
CN108085340B (zh) * 2017-12-07 2020-07-07 北京市肿瘤防治研究所 一种同时表达靶向cd19和cd20的car与pd1-cd28嵌合受体的慢病毒载体
WO2019118508A1 (en) * 2017-12-12 2019-06-20 The Trustees Of The University Of Pennsylvania Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
CN111542594A (zh) 2017-12-22 2020-08-14 菲特治疗公司 增强的免疫效应细胞和其用途
SG11202006606YA (en) 2018-01-12 2020-08-28 Curocell Inc Enhanced immune cells using dual shrna and composition including the same
TW201940182A (zh) 2018-01-22 2019-10-16 美商安德賽特公司 Car t 細胞之使用方法
AU2019243315A1 (en) 2018-03-29 2020-09-24 Fate Therapeutics, Inc. Engineered immune effector cells and use thereof
BR112020020245A2 (pt) 2018-04-05 2021-04-06 Editas Medicine, Inc. Métodos de produzir células expressando um receptor recombinante e composições relacionadas
CN112566698A (zh) 2018-04-05 2021-03-26 朱诺治疗学股份有限公司 T细胞受体和表达该t细胞受体的工程化细胞
WO2019213282A1 (en) 2018-05-01 2019-11-07 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
WO2019237035A1 (en) 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
SG11202011830SA (en) 2018-06-13 2020-12-30 Novartis Ag Bcma chimeric antigen receptors and uses thereof
CN110615842B (zh) * 2018-06-20 2023-05-09 上海隆耀生物科技有限公司 一种包含共刺激受体的嵌合抗原受体及应用
CN110257338B (zh) * 2018-06-21 2022-08-26 上海斯丹赛生物技术有限公司 嵌合细胞因子受体
US10780121B2 (en) 2018-08-29 2020-09-22 Shattuck Labs, Inc. FLT3L-based chimeric proteins
JP2022502037A (ja) 2018-09-28 2022-01-11 マサチューセッツ インスティテュート オブ テクノロジー コラーゲンに局在化される免疫調節分子およびその方法
US20220047633A1 (en) 2018-09-28 2022-02-17 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
AU2020232597A1 (en) 2019-03-01 2021-08-19 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
JP2022522654A (ja) * 2019-03-01 2022-04-20 アロジーン セラピューティクス，インコーポレイテッド Ｐｄ－１外部ドメインを担持するキメラサイトカイン受容体
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
KR20220081972A (ko) * 2019-07-17 2022-06-16 주식회사 큐로셀 이중 shrna를 이용하는 향상된 면역 세포 및 이를 포함하는 조성물
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
CN114945382A (zh) 2019-11-26 2022-08-26 诺华股份有限公司 Cd19和cd22嵌合抗原受体及其用途
AR120566A1 (es) 2019-11-26 2022-02-23 Novartis Ag Receptores de antígeno quiméricos y sus usos
CN115175929A (zh) 2020-02-24 2022-10-11 艾洛基治疗公司 活性增强的bcma car-t细胞
JP2023517063A (ja) 2020-03-10 2023-04-21 マサチューセッツ インスティテュート オブ テクノロジー 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物
CN115485295A (zh) 2020-03-10 2022-12-16 麻省理工学院 NPM1c阳性癌症的免疫疗法的组合物和方法
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
WO2022104109A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2023222829A1 (en) * 2022-05-17 2023-11-23 Centre Hospitalier Universitaire Vaudois Designed biosensors for enhanced t cell therapy
CN116925236B (zh) * 2023-05-12 2024-06-04 上海恩凯细胞技术有限公司 嵌合转换受体及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5199942A (en) 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
GB9125768D0 (en) 1991-12-04 1992-02-05 Hale Geoffrey Therapeutic method
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
PT1210428E (pt) * 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
AU1086501A (en) 1999-10-15 2001-04-30 Carnegie Institution Of Washington Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
JP4723782B2 (ja) * 2000-01-03 2011-07-13 ティーアール アソシエイツ，エル．エル．シー． 新規なキメラ蛋白質及び該蛋白質の使用方法
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
GB0225279D0 (en) 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
US20050113564A1 (en) * 2003-11-05 2005-05-26 St. Jude Children's Research Hospital Chimeric receptors with 4-1BB stimulatory signaling domain
US7285522B2 (en) 2004-08-25 2007-10-23 The Clorox Company Bleaching with improved whitening
ATE515512T1 (de) 2005-05-12 2011-07-15 Zymogenetics Inc Zusammensetzungen und verfahren zur modulierung von immunreaktionen
KR101514463B1 (ko) * 2005-06-08 2015-04-28 다나-파버 캔서 인스티튜트 인크. 예정 세포사 1(ｐｄ-1) 경로를 억제함으로써 지속 감염 및 암을 치료하기 위한 방법 및 조성물
JP2006345852A (ja) * 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
DK3006459T3 (da) * 2008-08-26 2021-12-06 Hope City Fremgangsmåde og sammensætninger til forbedring af t-cellers antitumoreffektorfunktion
EP2342228B1 (en) * 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
LT2519543T (lt) * 2009-12-29 2016-10-10 Emergent Product Development Seattle, Llc Heterodimerus rišantys baltymai ir jų panaudojimas
CN107266584B (zh) * 2011-07-29 2022-05-13 宾夕法尼亚大学董事会 转换共刺激受体

Also Published As

Publication number Publication date
MA35360B1 (fr) 2014-08-01
IL230496A0 (en) 2014-03-31
WO2013019615A3 (en) 2014-05-08
ES2723181T3 (es) 2019-08-22
US20140219975A1 (en) 2014-08-07
EP3549611A1 (en) 2019-10-09
JP2018148896A (ja) 2018-09-27
JP2024020529A (ja) 2024-02-14
EP3915588A1 (en) 2021-12-01
CN114835823A (zh) 2022-08-02
AU2012290342A1 (en) 2014-01-30
ZA201400477B (en) 2015-09-30
BR112014002006A2 (pt) 2017-02-21
MX2014001222A (es) 2014-09-15
CN104114233B (zh) 2021-11-12
CO6862107A2 (es) 2014-02-10
ECSP14013186A (es) 2014-03-31
US10981969B2 (en) 2021-04-20
JP7394093B2 (ja) 2023-12-07
JP7000242B2 (ja) 2022-02-04
JP6334398B2 (ja) 2018-05-30
EP2736540A2 (en) 2014-06-04
CL2014000195A1 (es) 2014-08-08
TN2014000020A1 (en) 2015-07-01
EP2736540A4 (en) 2015-04-29
GT201400015A (es) 2014-12-16
KR20140045533A (ko) 2014-04-16
JP2021192623A (ja) 2021-12-23
EP3549611B1 (en) 2021-06-30
CN107266584B (zh) 2022-05-13
CN104114233A (zh) 2014-10-22
JP2014524234A (ja) 2014-09-22
ES2888651T3 (es) 2022-01-05
EP2736540B1 (en) 2019-03-13
PE20141520A1 (es) 2014-11-17
CA2842368A1 (en) 2013-02-07
CN107266584A (zh) 2017-10-20
WO2013019615A2 (en) 2013-02-07
US20190345219A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
EA201490364A1 (ru) Костимулирующие рецепторы-переключатели
PH12019500781A1 (en) IL15/IL15Ra HETERODIMERIC FC-FUSION PROTEINS
NZ630854A (en) Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
MX2018013738A (es) Anticuerpos que comprenden dominios constantes quimericos.
WO2014144960A3 (en) Fc variants
MX371384B (es) Receptor antigenico quimerico.
EA201790934A1 (ru) ВАРИАНТЫ ИНТЕРФЕРОНА α2b
BR112015009924A2 (pt) formulações de proteína imunoglobulina de domínio variável duplo estáveis
MX2016008540A (es) Variantes de region fc con propiedades de union al receptor fc neonatal (fcrn).
EA201591331A1 (ru) Антагонисты il-33 и их применение
EA201391298A1 (ru) Неводные концентрированные суспензионные композиции с пониженной вязкостью на основе антител
WO2014140904A3 (en) Antibodies to mica and micb proteins
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
MX357944B (es) Variantes anticuerpos y usos de las mismas.
WO2012158818A3 (en) Multi-specific fab fusion proteins and methods of use
EA201791134A1 (ru) Полипептиды химерного фактора viii и их применение
AR083454A1 (es) Antigeno de citomegalovirus
EA201390666A1 (ru) Cxcr2-связывающие полипептиды
UY33983A (es) Proteínas de Unión de Tipo Anticuerpo con Región Variable Dual que Tienen Orientación de la Región de Unión con Entrecruzamiento.
EA201790309A1 (ru) Антитела к fap, способы их получения и применения
UA108778C2 (xx) Протираковий злитий протеїн
WO2014150748A3 (en) Stabilized single human cd4 domains and fusion proteins
WO2013025846A3 (en) Transferrin-tumstatin fusion protein and methods for producing and using the same
GB201103453D0 (en) Kinase substrate sensor